PE13232006A1 - Antibodies directed against the beta amyloid peptide and methods using the same - Google Patents

Antibodies directed against the beta amyloid peptide and methods using the same

Info

Publication number
PE13232006A1
PE13232006A1 PE2006000443A PE0004432006A PE13232006A1 PE 13232006 A1 PE13232006 A1 PE 13232006A1 PE 2006000443 A PE2006000443 A PE 2006000443A PE 0004432006 A PE0004432006 A PE 0004432006A PE 13232006 A1 PE13232006 A1 PE 13232006A1
Authority
PE
Peru
Prior art keywords
seq id
methods
same
directed against
antibodies directed
Prior art date
Application number
PE2006000443A
Other languages
Spanish (es)
Inventor
Arnon Rosenthal
Jaume Pons
Wei-Hsien Ho
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US67609305P priority Critical
Priority to US70481805P priority
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE13232006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of PE13232006A1 publication Critical patent/PE13232006A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL SELECCIONADO DE IgG1, IgG2; It REFERS TO A SELECTED MONOCLONAL ANTIBODY IgG1, IgG2; IgG3 E IgG4 EL CUAL SE UNE A UN PEPTIDO AB, ESPECIFICAMENTE A UN EPITOPO EN AB1-40 QUE INCLUYE LOS AMINOACIDOS 25-34 Y 40 CON UNA AFINIDAD DE APROXIMADAMENTE DE 5nM O MENOS. IgG3 and IgG4 which binds to a peptide AB specifically to an epitope on AB1-40 including amino acids 25-34 and 40 with an affinity of about 5nm or less. DICHO ANTICUERPO COMPRENDE UNA REGION VARIBLE DE CADENA PESADA SELECCIONADA DE SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 Y SEQ ID NO:5; Said antibody comprises a heavy chain varible region selected from SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5; Y UNA REGION VARIBLE DE CADENA LIGERA SELECCIONADA DE SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:7 Y SEQ ID NO:8. And a region varible light chain selected from SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8. EL ANTICUERPO NO ES EL ANTICUERPO 2294. SON UTILES EN EL TRATAMIENTO DE ALZHEIMER ANTIBODY IS NOT THE ANTIBODY 2294. ARE USEFUL IN TREATING ALZHEIMER
PE2006000443A 2005-04-29 2006-04-27 Antibodies directed against the beta amyloid peptide and methods using the same PE13232006A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US67609305P true 2005-04-29 2005-04-29
US70481805P true 2005-08-01 2005-08-01

Publications (1)

Publication Number Publication Date
PE13232006A1 true PE13232006A1 (en) 2007-02-09

Family

ID=37308500

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000443A PE13232006A1 (en) 2005-04-29 2006-04-27 Antibodies directed against the beta amyloid peptide and methods using the same

Country Status (30)

Country Link
US (4) US7763250B2 (en)
EP (1) EP1877442B1 (en)
JP (1) JP4280300B2 (en)
KR (2) KR100994599B1 (en)
CN (1) CN102617733B (en)
AP (1) AP200704217A0 (en)
AR (1) AR053252A1 (en)
AU (1) AU2006242546B2 (en)
BR (1) BRPI0607671A2 (en)
CA (1) CA2605759C (en)
CR (1) CR9478A (en)
DK (1) DK1877442T3 (en)
DO (1) DOP2006000099A (en)
EA (1) EA016193B9 (en)
ES (1) ES2597403T3 (en)
GE (1) GEP20125385B (en)
GT (1) GT200600182A (en)
HK (1) HK1117543A1 (en)
IL (1) IL186671A (en)
MA (1) MA29409B1 (en)
MX (1) MX2007013626A (en)
MY (1) MY148086A (en)
NO (1) NO20076021L (en)
NZ (1) NZ562589A (en)
PE (1) PE13232006A1 (en)
SV (1) SV2008002511A (en)
TN (1) TNSN07401A1 (en)
TW (1) TWI501975B (en)
UY (1) UY29504A1 (en)
WO (1) WO2006118959A2 (en)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EA200901140A1 (en) 2007-03-01 2010-04-30 Пробиодруг Аг New use of glutaminyl cycllase inhibitors
SG190665A1 (en) 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
CN101432302A (en) 2005-11-30 2009-05-13 艾博特公司;艾博特股份有限两合公司 Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibod
AU2006326284B2 (en) 2005-12-12 2013-06-06 Ac Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
SI2047863T1 (en) 2006-06-08 2013-11-29 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR101735257B1 (en) * 2007-01-05 2017-05-12 유니버시티 오브 취리히 Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
US7939075B2 (en) 2007-01-11 2011-05-10 Philipps-Universitaet Marburg Human monoclonal anti-amyloid-beta antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US20090099783A1 (en) * 2007-06-08 2009-04-16 Barry Reisberg Stage Specific Prognostic In Vivo Markers of Brain Aging and Dementia
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
KR20100074181A (en) 2007-09-13 2010-07-01 델레넥스 쎄라퓨틱스 아게 HUMANIZED ANTIBODIES AGAINST THE β-AMYLOYD PEPTIDE
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Change the method for isoelectric point of antibody using the amino acid substitution of CDR
PE07112009A1 (en) 2007-09-26 2009-07-15 Chugai Pharmaceutical Co Ltd Constant region antibody mutant
EP2238166B1 (en) 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
US20100297013A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
KR101595134B1 (en) 2007-12-05 2016-02-17 추가이 세이야쿠 가부시키가이샤 Therapeutic agent for pruritus
KR20160062207A (en) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
JP5139517B2 (en) * 2008-12-05 2013-02-06 中外製薬株式会社 Anti-NR10 antibody and use thereof
DK2236604T3 (en) 2007-12-05 2016-10-03 Chugai Pharmaceutical Co Ltd The anti-NR10 antibody and use thereof
EA022913B1 (en) * 2007-12-11 2016-03-31 Глаксо Груп Лимитед antigen-binding proteins
ES2671403T3 (en) 2008-04-11 2018-06-06 Chugai Seiyaku Kabushiki Kaisha Antigen binding molecule capable of binding to two or more antigen molecules repeatedly
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
MX2011006422A (en) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies.
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
FR2942799B1 (en) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anti-rhesus monoclonal antibody
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
BR112012022478A2 (en) 2010-03-10 2017-02-14 Probiodrug Ag heterocyclic glutaminyl cyclase inhibitors (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US9023607B2 (en) * 2010-04-26 2015-05-05 Intellectual Discovery Co., Ltd. Method for early diagnosis of alzheimer'S disease using phototransistor
MX341369B (en) 2010-07-30 2016-08-17 Genentech Inc * Safe and functional humanized anti beta-amyloid antibody.
WO2015053624A2 (en) * 2013-10-07 2015-04-16 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Antisense oligonucleotide directed removal of proteolytic cleavage sites, the hchwa-d mutation, and trinucleotide repeat expansions
CN105348387A (en) 2010-08-14 2016-02-24 Abbvie 公司 Amyloid-[beta] binding proteins
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
ES2602794T3 (en) 2011-03-31 2017-02-22 Pfizer Inc Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh Anti-alpha synuclein binding molecules
CN103687876A (en) * 2011-07-15 2014-03-26 詹森药业有限公司 Monoclonal antibodies specific for beta-amyloid x-37 and uses thereof
JP6043355B2 (en) 2011-08-31 2016-12-14 ファイザー・インク Hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compound
EP2852597B1 (en) 2012-05-04 2016-06-08 Pfizer Inc Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
BR112014032913A2 (en) 2012-06-29 2017-06-27 Pfizer novel 4- (amino-substituted) -7h-pyrrolo [2,3-d] pyrimidines as lrrk2 inhibitors
JP2015529239A (en) 2012-09-20 2015-10-05 ファイザー・インク Alkyl-substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
SI2897956T1 (en) 2012-09-21 2017-02-28 Pfizer Inc. Novel bicyclic pyridinones
JP2016502978A (en) 2012-12-11 2016-02-01 ファイザー・インク Hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of BACE1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP6505023B2 (en) 2013-02-19 2019-04-24 ファイザー・インク Azabenzimidazole compounds as inhibitors of PDE4 isozymes for treating CNS and other disorders
KR101503031B1 (en) 2013-04-25 2015-03-18 한국화학연구원 Lead precursors with aminothiolate, preparation method thereof and process for the formation of thin films using the same
FR3007988B1 (en) * 2013-07-04 2015-09-25 Centre Nat Rech Scient Inhibition of betaapp protein synthesis or abeta peptide activity in choroid plexuses.
JP6425717B2 (en) 2013-10-04 2018-11-21 ファイザー・インク Novel bicyclic pyridinone as a gamma secretase modulator
JP6487921B2 (en) 2013-12-17 2019-03-20 ファイザー・インク Novel 3,4-disubstituted-1H-pyrrolo [2,3-b] pyridines and 4,5-disubstituted-7H-pyrrolo [2,3-c] pyridazines as LRRK2 inhibitors
BR112016022519A8 (en) 2014-04-01 2018-03-06 Pfizer chromene and 1,1a, 2,7b-tetrahydrocyclopropa [c] chromene pyridopyrazinedione as gamma secretase modulators
WO2015155626A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
JP6410810B2 (en) * 2014-05-22 2018-10-24 株式会社島津製作所 Surrogate biomarker for evaluating amyloid β peptide accumulation state in brain and analysis method thereof
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (en) 2014-08-06 2019-09-30 Pfizer Imidazopyridazine compounds
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN104558172A (en) * 2015-01-04 2015-04-29 东南大学 Single-domain heavy-chain nanobody for amyloid-beta and application of single-domain heavy-chain nanobody
PE13182017A1 (en) 2015-02-03 2017-09-07 Pfizer Ciclopropabenzofuranil-piridopirazindionas novel
BR112017026191A2 (en) 2015-06-17 2018-08-14 Pfizer tricyclic compounds and their use as phosphodiesterase inhibitors
KR20180050407A (en) 2015-09-14 2018-05-14 화이자 인코포레이티드 Imidazo [4,5-c] quinoline and imidazo [4,5-c] [1,5] naphthyridine derivatives as LRRK2 inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
AU2017223132A1 (en) 2016-02-23 2018-07-26 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
KR20190035713A (en) 2016-07-01 2019-04-03 화이자 인코포레이티드 5,7-Dihydro-pyrrolo-pyridine derivatives for the treatment of neurological and neurodegenerative diseases
SG11201908322WA (en) 2017-03-10 2019-10-30 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2018163030A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
WO2018234953A1 (en) 2017-06-22 2018-12-27 Pfizer Inc. Dihydro-pyrrolo-pyridine derivatives
WO2019036725A2 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
WO2019183636A1 (en) 2018-03-23 2019-09-26 Pfizer Inc. Piperazine azaspiro derivaves

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4403112A (en) * 1981-05-18 1983-09-06 Modafferi Acoustical Systems, Ltd. Phase shift low frequency loudspeaker system
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) * 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4891268A (en) * 1984-03-26 1990-01-02 Metal Coatings International Inc. Coated metal substrates with anticorrosion coating composition
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683202B1 (en) * 1985-03-28 1990-11-27 Cetus Corp
GB8508845D0 (en) * 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4683195B1 (en) * 1986-01-30 1990-11-27 Cetus Corp
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL85035D0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biolog Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
WO1991016628A1 (en) 1990-04-24 1991-10-31 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Making and using transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AT164395T (en) * 1990-12-03 1998-04-15 Genentech Inc A method for enrichment of protein variants with altered binding properties
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5278299A (en) * 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co., Inc. A method for reducing the immunogenicity of antibody variable domains
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114324D0 (en) * 1991-07-03 1991-08-21 Kontor Moulding Systems Ltd Injection moulding of thermoplastic polymers
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994009370A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
US5962463A (en) 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
WO1994009371A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AT239797T (en) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antibodies against beta-amyloid or derivative thereof and its use
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US6107050A (en) * 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0728215B1 (en) 1993-10-20 2002-02-20 Duke University METHOD OF BINDING MATERIAL TO THE Beta-AMYLOID PEPTIDE
US5525126A (en) * 1994-10-31 1996-06-11 Agricultural Utilization Research Institute Process for production of esters for use as a diesel fuel substitute using a non-alkaline catalyst
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6436908B1 (en) * 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
US6221645B1 (en) * 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH11507538A (en) * 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド Assay for detecting β- secretase, antibodies against β- secretase and β- secretase inhibitors
WO1997012992A2 (en) 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5976817A (en) 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6221670B1 (en) * 1997-03-21 2001-04-24 Scios Inc. Methods to identify β-amyloid reducing agents
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1002862A1 (en) 1998-11-12 2000-05-24 Nitsch, Roger M., Prof. Dr. Methods of diagnosing or treating neurological diseases
US6143171A (en) 1999-04-07 2000-11-07 Van Aarsen; Freda Martha Magnetic device for treatment of fluids
WO2000067033A1 (en) * 1999-05-03 2000-11-09 Evotec Biosystems Ag Methods of diagnosing or treating alzheimer's disease
WO2000077178A1 (en) 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
US6255054B1 (en) * 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001077167A2 (en) * 2000-04-05 2001-10-18 University Of Tennessee Research Corporation Methods of investigating, diagnosing, and treating amyloidosis
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
AU1225702A (en) * 2000-09-19 2002-04-02 Evotec Neurosciences Gmbh Methods and compounds for treating brain amyloidosis
PE05742002A1 (en) 2000-12-06 2002-07-02 Wyeth Corp Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1421607A2 (en) 2001-02-12 2004-05-26 ASM America, Inc. Improved process for deposition of semiconductor films
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US6573276B2 (en) * 2001-05-09 2003-06-03 Boehringer Ingelheim Pharma Kg Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesis
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
US20040241164A1 (en) 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
WO2003039462A2 (en) * 2001-11-02 2003-05-15 Tanox, Inc. B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
US7060270B2 (en) * 2001-11-02 2006-06-13 Diagenics International Corporation Methods and compositions of monoclonal antibodies specific for beta-amyloid proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003086310A2 (en) * 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
ES2318123T3 (en) * 2002-04-25 2009-05-01 Eli Lilly And Company Procedure to treat anxiety in subjects of advanced age.
EP1535075A2 (en) 2002-06-20 2005-06-01 Axonyx, Inc. Assay method
AUPS306402A0 (en) 2002-06-20 2002-07-11 Aguilar, Marie-Isabel Assay method
US8871447B2 (en) 2002-09-12 2014-10-28 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
ES2201929B1 (en) 2002-09-12 2005-05-16 Araclon Biotech, S.L. Polyclonal antibodies, method of preparation and use of the same.
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
MXPA05003621A (en) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof.
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
ES2697876T3 (en) 2002-12-24 2019-01-29 Rinat Neuroscience Corp Anti-NGF antibodies and methods of using them
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
AU2004274390A1 (en) 2003-03-28 2005-03-31 Jacqueline M. Benson Anti-amyloid antibodies, compositions, methods and uses
AU2003276107A1 (en) 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
ES2246177B1 (en) 2003-05-08 2007-03-01 Universidad De Zaragoza. Use of antibodies for the treatment of amyloid diseases.
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005011599A2 (en) 2003-08-01 2005-02-10 Northwestern University Antibodies specific for toxic amyloid beta protein oligomers
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
WO2005025516A2 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
SG190665A1 (en) * 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
GT200600031A (en) 2005-01-28 2006-08-29 Formulation anti beta
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same

Also Published As

Publication number Publication date
HK1117543A1 (en) 2013-08-30
KR100994599B1 (en) 2010-11-15
TWI501975B (en) 2015-10-01
WO2006118959A3 (en) 2007-05-10
GEP20125385B (en) 2012-01-25
SV2008002511A (en) 2008-04-11
JP2008538925A (en) 2008-11-13
DOP2006000099A (en) 2006-10-31
NO20076021L (en) 2008-01-28
GT200600182A (en) 2007-02-14
TNSN07401A1 (en) 2009-03-17
IL186671D0 (en) 2008-01-20
JP4280300B2 (en) 2009-06-17
EA016193B1 (en) 2012-03-30
US20110044985A1 (en) 2011-02-24
CN102617733B (en) 2016-01-20
US20060292152A1 (en) 2006-12-28
MA29409B1 (en) 2008-04-01
TW200718710A (en) 2007-05-16
ES2597403T3 (en) 2017-01-18
KR20100120242A (en) 2010-11-12
AU2006242546B2 (en) 2011-04-21
US20130236451A1 (en) 2013-09-12
CN102617733A (en) 2012-08-01
CR9478A (en) 2007-12-04
CA2605759A1 (en) 2006-11-09
EP1877442A2 (en) 2008-01-16
MY148086A (en) 2013-02-28
US7763250B2 (en) 2010-07-27
KR20080005231A (en) 2008-01-10
UY29504A1 (en) 2006-10-31
IL186671A (en) 2014-01-30
DK1877442T3 (en) 2016-09-26
AU2006242546A1 (en) 2006-11-09
US20160096884A1 (en) 2016-04-07
NZ562589A (en) 2009-07-31
EA200702095A1 (en) 2008-04-28
EP1877442B1 (en) 2016-08-17
WO2006118959A2 (en) 2006-11-09
EA016193B9 (en) 2012-08-30
MX2007013626A (en) 2008-01-24
AR053252A1 (en) 2007-04-25
CA2605759C (en) 2014-06-10
BRPI0607671A2 (en) 2009-09-22
US8398978B2 (en) 2013-03-19
KR101130874B1 (en) 2012-03-28
AP200704217A0 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
ES2569409T3 (en) Anti-CTLA-4 antibody compositions
JO3000B1 (en) Antibody Formulations.
ES2567402T3 (en) Anti CD22 antibodies, their immunoconjugates and their uses
DE60333732D1 (en) Internalization of anti cd74 monoclonal antibodies and their uses
ES2533242T3 (en) Prevention and treatment of eye conditions associated with complement
AR084747A1 (en) Anti-CD38 antibodies
CY1110877T1 (en) Change of the families ASSOCIATION me fcrn or half-serum antibodies by mutagenesis
PE00462009A1 (en) Antibody humanized recombinant anti-interleukin 10
GT200600043A (en) Variants of an antibody and uses thereof
WO2006085967A3 (en) OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
SG170110A1 (en) Identification and engineering of antibodies with variant heavy chains and methods of using same
AR061246A1 (en) Anti- dill4 and methods that use
NO340443B1 (en) Anti-P-selectin antibodies, composition comprising the same, methods of preparing such and uses thereof for the prevention and treatment of diseases.
AR053814A2 (en) Humanized monoclonal antibody that binds specifically to the CD80 antigen and its use in the preparation of a pharmaceutical composition
NZ612796A (en) A ca6 antigen-specific cytotoxic conjugate and methods of using the same
EP2388277A3 (en) Human anti-B7RP1 neutralizing antibodies
NO20076673L (en) Antibodies directed against CD20 and uses thereof
MXPA06001664A (en) Cd20-binding polypeptide compositions.
AR033978A1 (en) Antibody molecule having specificity for human tumor necrosis factor alpha and uses thereof
CL2010000426A1 (en) human antibody that binds to the ligand for the OX40 (OX40L or gp34) human; Method of production; and pharmaceutical composition comprising (div. sol. No. 2389-05).
RS53924B1 (en) Notch-binding agents and antagonists and methods of use thereof
NO20071419L (en) Polypeptides with altered effector function
DOP2009000269A (en) Humanized antibodies against ab globulomero (20-42) and their uses
UA89350C2 (en) Humanized antibody that specifically binds human cd20
CY1112909T1 (en) Antibodies directed against the angiopoietin (angiopoietin) -2 AND USES these

Legal Events

Date Code Title Description
FC Refusal